Arca Biopharma Stock Leadership

ABIO -  USA Stock  

USD 2.35  0.06  2.62%

Arca Biopharma employes about 11 people. The company is managed by 9 executives with total tenure of roughly 72 years, averaging almost 8.0 years of service per executive having 1.22 employees per reported executive. Inspection of Arca Biopharma management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Arca Biopharma future performance.
Please continue to Trending Equities.
  
Refresh
  Michael Bristow  CEO
President CEO, Director
  Robert Conway  Chairman
Chairman of the Board

Arca Biopharma Return on Sales

(0.24)

Share

Arca Biopharma Management Team Effectiveness

Arca Biopharma has return on total asset (ROA) of (20.93) % which means that it has lost $20.93 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (35.07) %, meaning that it created substantial loss on money invested by shareholders. Arca Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -0.34. The value of Return on Average Equity is estimated to slide to -0.36. Arca Biopharma Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 59.26 Million

Arca Biopharma Quarterly Total Assets

51.01 Million

Share
Arca Biopharma Weighted Average Shares is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 15 Million. Weighted Average Shares Diluted is expected to rise to about 15 M this year, although the value of Issuance Purchase of Equity Shares will most likely fall to about 21.1 M.

Arca Biopharma Workforce Comparison

Arca Biopharma is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 1,382. Arca Biopharma maintains roughly 11.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.

Arca Biopharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arca Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arca Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arca Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Arca Biopharma Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Arca Biopharma Price Series Summation is a cross summation of Arca Biopharma price series and its benchmark/peer.
.

Arca Biopharma Notable Stakeholders

An Arca Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arca Biopharma often face trade-offs trying to please all of them. Arca Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arca Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Bristow - President CEO, DirectorProfile
Robert Conway - Chairman of the BoardProfile
Thomas Keuer - COOProfile
Christopher Ozeroff - Sr. VP, General Counsel and SecretaryProfile
Raymond Woosley - DirectorProfile
Daniel Mitchell - DirectorProfile
Linda Grais - Lead Independent DirectorProfile
Anders Hove - DirectorProfile
Brian Selby - Chief Accounting Officer and VP of Fin.Profile

About Arca Biopharma Management Performance

The success or failure of an entity such as Arca Biopharma often depends on how effective the management is. Arca Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arca Biopharma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arca Biopharma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Average Assets(0.31) (0.34) 
Return on Average Equity(0.33) (0.36) 
Return on Invested Capital 20.35  19.07 
Return on Sales(0.24) (0.26) 
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
The data published in Arca Biopharma's official financial statements usually reflect Arca Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Arca Biopharma. For example, before you start analyzing numbers published by Arca Biopharma accountants, it's critical to develop an understanding of what Arca Biopharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Arca Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arca Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Arca Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arca Biopharma. Please utilize our Beneish M Score to check the likelihood of Arca Biopharma's management to manipulate its earnings.

Arca Biopharma Workforce Analysis

Traditionally, organizations such as Arca Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arca Biopharma within its industry.

Arca Biopharma Manpower Efficiency

Return on Arca Biopharma Manpower

Revenue Per Employee2.3 M
Revenue Per Executive2.8 M
Net Loss Per Employee1.7 M
Net Loss Per Executive2.1 M
Please continue to Trending Equities. Note that the Arca Biopharma information on this page should be used as a complementary analysis to other Arca Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Arca Biopharma Stock analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.